Insmed Incorporated

NASDAQ:INSM

Biotechnology

Healthcare
$119.80 -2.77%

-$2.73 today

Market cap
$26.28B
Beta
0.77
P/E (TTM)
-17.4
EPS (TTM)
-$5.49
52W Low $90.39High $212.75

Volume 1.94M

Average 3.31M

INSM Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Insmed IncorporatedNASDAQ: INSM

Accounts Payables · Q2 FY2026 · quarter ended Jun 2026

Accounts payables grows, but more slowly than its trailing trend

Q2 FY2026 accounts payables of $68.82M rose 168.2% year over year, behind the +2736.6% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at +26.0% a year.

Context

  • Accounts payables amounted to 16.5% of revenue in FY2025, up 4.2 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +168.2% toward the trailing-twelve-month pace of +2736.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$68.82M+303.2% QoQ
Last fiscal yearDec 2025
$100.07M+124.4% YoY
LTMJun 2026
$170.85M+2736.6% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+168.2%——
1 year+124.4%——
3-year CAGR+26.0%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
100.07M USD
Year-over-year change
+124.4%

Accounts Payables vs competitors

How INSM compares with its peers on the latest reported figures

  • INSM's LTM Jun 2026 accounts payables of $170.85M is the largest of the 4 companies compared; the peer median is $1.31M.
  • Its year-over-year change of +2736.6% is the highest of 3, against a peer median of -320.2%.
  • Accounts payables amounts to 15.0% of revenue for INSM, versus a peer median of 2.6%.
INSM Competitors Peer median
Accounts Payables for INSM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INSMInsmed IncorporatedLTM Jun 2026$170.85M +2736.6%+26.0%15.0%
UTHRUnited Therapeutics CorporationLTM Jun 2026$81.2M ——2.6%
LQDALiquidia CorporationLTM Jun 2026$11.7M -361.8%—2.6%
TBPHTheravance Biopharma, Inc.LTM Mar 2026$1.31M -278.7%—1.2%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding INSM) $1.31M-320.2%—2.6%

Competitors are the stored peer set for INSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(434.65M)(481.53M)(749.57M)(913.77M)(1.28B)
Depreciation & Amortization14.18M10.33M10.58M11.01M16.45M
Deferred Income Tax17.69M0000
Stock-Based Compensation46.02M57.69M74.78M96.84M152.71M
Change in Working Capital(58.58M)6.58M(39.22M)(3.18M)(80.3M)
Accounts Receivables(8.12M)(6.42M)(11.96M)(12.93M)(88.31M)
Inventory(17.46M)(1.71M)(13.61M)(17.04M)(31.52M)
Accounts Payables(7.58M)50.01M15.16M44.59M100.07M
Other Working Capital(25.43M)(35.3M)(28.8M)(17.79M)(60.55M)
Other Non-Cash Items52.04M6.5M167.18M125.22M252.9M
Operating Cash Flow(363.3M)(400.44M)(536.25M)(683.88M)(935.01M)
Capital Expenditures(7.29M)(9.88M)(13.29M)(21.92M)(32.56M)
Acquisitions (Net)(6.7M)24.71M3.42M00
Purchases of Investments(50.29M)(99.71M)(588.73M)(1.58B)(2.09B)
Sales of Investments57M75M375M1.02B2.09B
Other Investing Activities(57M)(24.71M)00(30M)
Investing Cash Flow(64.29M)(34.58M)(223.6M)(583.18M)(64.58M)
Debt Repayment336.34M349.4M(1.22M)147.39M(4.93M)
Common Stock Issued269.89M292.15M152.48M1.08B959M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities6.32M151.72M17.18M109.51M0
Financing Cash Flow612.55M793.27M168.44M1.34B954.07M
Effect of Forex Changes(933K)(996K)(250K)(1.31M)931K
Net Change in Cash184.03M357.25M(591.66M)72.66M(44.59M)
Free Cash Flow(370.59M)(410.32M)(549.54M)(705.81M)(967.58M)

Insmed Incorporated

NASDAQ:INSM

Intrinsic Alpha fair value

Locked

Current Price

$119.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.